OrbiMed raises $942m royalty fund; 60% for biopharma
This article was originally published in Scrip
Executive Summary
OrbiMed has raised $942m for its second health care royalty and credit opportunities fund and Carter Neild, a partner in the New York-based investment firm, tells Scrip that about 60% of OrbiMed Royalty Corporation II will be invested in biopharmaceutical royalty streams and debt arrangements.